Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$65.34 USD

65.34
734,584

+0.54 (0.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 281 - 300 ( 304 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 281

10/28/2011

Company Report

Pages: 10

3Q11 Update: ‘357 Partnership Talks Advance - Multi-Dose Phase 2 Data in ALS by YE11

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 282

10/19/2011

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 283

10/18/2011

Daily Note

Pages: 3

Course Correction to Prioritize the Lead Assets

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 284

10/18/2011

Daily Note

Pages: 3

Course Correction to Prioritize the Lead Assets

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 285

10/13/2011

Daily Note

Pages: 4

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 286

10/12/2011

Company Report

Pages: 49

We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 100.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 287

10/12/2011

Daily Note

Pages: 3

We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.

Provider: RODMAN & RENSHAW, CO.

Analyst: NOCHOMOVITZ Y

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 288

06/14/2011

Company Report

Pages: 4

Dropping Coverage

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 289

04/27/2011

Company Report

Pages: 5

Reports Q1:11 Earnings and Updates Clinical Developments

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 290

03/25/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 291

02/14/2011

Company Report

Pages: 5

Reports Q4:10 Earnings and Updates Clinical Developments

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 292

12/13/2010

Company Report

Pages: 7

357 PIIa Results in ALS Setting - Promising Initial Progress.

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 293

11/26/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 294

11/12/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 295

10/29/2010

Company Report

Pages: 4

Q3:10 Earnings a Non-Event, Focus Remains on Full ALS Data in December

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 296

09/24/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 297

09/17/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 298

08/20/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 299

07/29/2010

Company Report

Pages: 5

Reports Q2:10 Earnings and Provides Update to CK-‘357 and omecamtiv mecarbil Programs

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 300

06/11/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party